Gamma Therapeutics (GT) is an early stage biotechnology venture developing patented and patent-pending medical devices for cardiovascular disease risk assessment, surgical therapy and hemorrhage control based upon a single technology platform of human biocompatible clotting proteins.

Gamma Therapeutics was incorporated in the State of Oregon in 2009 and launched as a biotechnology start-up in July, 2010. The founder, David H. Farrell, PhD, a 33-year researcher in coagulation, hemostasis and thrombosis research, is Chief Scientific Officer of Gamma Therapeutics and a Professor of Surgery in the Oregon Health & Science University (OHSU) Department of Surgical Medicine.  David F Eastman, MS, is the Chief Executive Officer with 35 years of life science and high technology marketing and executive management experience.

The company was originally funded with a $1.56 M grant from the National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI) to develop the GammaCoeur™ CVD Risk ELISA, a clinical diagnostic laboratory test for heart attack and stroke risk.  GammaCoeur is CE Marked in the European Union, completed an initial clinical trial with 10,601 cardiac at risk patients at the University of Vermont, is sold in the U.S. as a Laboratory Developed Test (LBT) /Research Use Only (RUO) test by ZEUS Scientific and is awaiting final FDA clearance in the U.S.

Gamma Therapeutics is headquartered in Portland, Oregon at the Oregon Translational Research and Development Institute (OTRADI) Business Incubator (OBI), 4640 SW Macadam Avenue, Portland, Oregon USA 97239.

Click here to download the Gamma Therapeutics Fact Sheet.

Copyright © 2010, Gamma Therapeutics, Inc. All rights reserved.